2025 Q4 -tulosraportti
Vain PDF
130 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·8 t sittenHi everyone, see the stock has risen A LOT in the last year. I actually know nothing about the company 😅. Should jrg buy? Or wait until it perhaps goes down?
Listen carefully now, I'm only saying it once Investormark You skip Viking Lotto and Lotto and Europott Other games e.g. horse betting per week it costs kr300,- and you skip all the beers in town approx kr. 700.- taxi home from town kr 500,- per week kr 1500,- month kr 6000, Voila, not hungover now you have kr 6000,- per month now you are on your way 4 months kr 24000,- then you have approx 2,500 shares wait 3 years then this can be good multiply it by kr 150 or kr 550 🙂- ·11 t sitten · MuokattuTime to give Investornytt and Teigland credit. This is well written. The share price has increased tenfold – now the real Circio journey begins https://www.investornytt.no/kommentar/tidoblet-kursen-na-begynner-den-virkelige-circio-reisen/541928 Circio has already been one of the year's biggest stock market rockets. After raising 628 million kroner, entering new international collaborations, and nominating an RNA heavyweight to the board, Espen Teigland believes the company has delivered a masterclass in biotechnological risk management and commercial positioning. FROM BIOTECH GNAT TO STOCK MARKET ROCKET: CEO Erik Digman Wiklund has lifted Circio from an overlooked biotech company to one of the year's biggest share price winners. After one tenfold increase, 628 million kroner raised, and several international collaborations in place, Wiklund believes the company can do it again. As a long-time observer and stock commentator, I have seen countless companies stumble into the same, well-known trap: One falls in love with one's own technology, burns through investors' capital on an expensive and solitary race towards the clinic, and ends up in an endless spiral of dilutive crisis emissions. Biotechnology on the Oslo Stock Exchange has therefore rightly gained a reputation as a binary roulette game. But what we are now witnessing from Circio after a formidable first half of 2026, appears to be something fundamentally different. The company is implementing a strategic shift that, in my opinion, makes them one of the most technologically and commercially exciting platform investments in Nordic biotech right now. The share has already increased tenfold in a short time. CEO Erik Digman Wiklund has previously stated to Investornytt that the company can do it again. After the milestones in the first half of the year, I do not believe the ambition appears less realistic – quite the opposite. The Achilles' heel in gene therapy To understand why these fresh milestones are so potent, we must delve into the scientific substance. Gene therapy has long struggled with a fundamental problem: delivery and expression. To get enough therapeutic protein produced in the body, patients often need to be given massive doses of viral vectors like AAV. This triggers immune responses, dangerous toxicity, and extreme production costs. Circio's proprietary circVec technology (based on circular RNA) addresses this by providing up to 75 times longer RNA half-life and up to 50 times higher protein expression than conventional mRNA vectors. Are you following? But it is the way the company is now commercializing and validating this that truly impresses me. Surgical intervention in the secretory bottleneck The partnership with Avenue Biosciences targets gene therapy's perhaps largest underutilized bottleneck – the cell's secretory pathways. Avenue uses machine learning to optimize signal peptides, i.e., the molecular codes that tell the cell to secrete the protein into the bloodstream rather than retaining it internally. When Circio now combines its long-lasting RNA expression with Avenue's ability to maximize secretion, they create a synergy that can dramatically reduce the required dose. If they prove that this combination works in vivo, circVec will go from being an interesting. Platform within more narrow gene therapy to becoming a plug-and-play solution for chronic diseases that require long-term expression of, for example, antibodies or peptides, such as e.g. rheumatism or obesity. An option on the future of immunotherapy Earlier this year, Circio announced several collaborations, including with Canadian Acuitas and German Tcelltech, where they aim for an even greater challenge: In vivo CAR-T cell therapy. Today, CAR-T is done ex vivo, where the patient's cells are harvested, manipulated in expensive laboratories over several weeks, and reinserted – a process that costs millions per patient. The entire industry is now chasing methods to inject the treatment directly into the body, but the use of viral vectors creates serious safety concerns. Acuitas develops LNP particles that can deliver genetic material specifically to the body's T-cells. There is currently enormous interest around in vivo (in the body) CAR-T and circRNA technology, which is clearly reflected in the market where companies like oRNA Tx, Orbital, and Sail Biomedicines have recently been acquired by Big Pharma for large sums for their programs. In this red-hot landscape, Tcelltech positions itself with a significant competitive advantage. The company possesses nanoSMAR, a non-viral, episomal DNA vector that stands out with its enormous cargo capacity. By combining this patented vector technology with the powerful gene expression from circVec, Tcelltech is now attempting to crack the very code for scalable cell therapy.Dr. Dinah Sah's professional seal of quality The perhaps most convincing indicator that Circio has moved into the elite league, we find neither in the test tubes nor in the partnerships, but in the nomination of Dr. Dinah Sah to the company's board. Sah is one of the pioneers behind modern RNA medicine. As former VP of Research at Alnylam Pharmaceuticals, she helped drive forward patisiran (ONPATTRO), the first approved RNAi therapy in history, before becoming CSO at Voyager Therapeutics, one of the pioneering companies in AAV gene therapy, which is Circio´s most advanced project. She knows exactly what it takes to get RNA and AAV technology through the regulatory needle's eye in the USA and all the way to clinical approval. Heavy, American research elite does not waste its time on castles in the air. Sah's entry is a professional endorsement in itself, and gives Circio an invaluable position when they are now to approach American venture capitalists and potential partners. 620 million in cash keeps the ghost of issuance away Ad All this professional foundation, however, rests on a solid financial ground. In the first half of 2026, the company carried out capital raises of approximately 620 million kroner. For a biotech investor, the absence of the famous "ghost of issuance" is alpha and omega. With this war chest, management has bought itself a solid runway well into 2030, with the goal of clinical initiation for the company's leading candidate in 2029. They are thus not forced to enter into suboptimal, rushed agreements with their back against the wall, but can negotiate with Big Pharma from a position of strength as preclinical data from the Avenue and Tcelltech collaborations mature. Shareholder verdict: A robust platform journey filled with value-driving triggers Although risk-free biotechnology does not exist, Circio shows how to systematically minimize company-specific risk. By diversifying the application areas, obtaining strong professional validation, and securing the cash, Circio transforms itself from a vulnerable single-product company to a unique and industry-leading technological platform concept. For shareholders, this means that the journey towards clinical initiation in 2029 will not be a long desert trek, but a period filled with continuous, value-driving triggers as technology synergies are confirmed in the market and the scope for partnership agreements grows. Circio steps out of the shadow and into the Main Index Also on the stock exchange, Circio is about to move up a division. DNB Carnegie expects the company to be included in both OSEBX and OSEFX at autumn's index rebalancing. If the prediction is confirmed, it can provide increased visibility, more institutional interest, and purchases from funds that follow the indices. This will in that case be yet another sign that Circio has gone from being an overlooked biotech gnat to a stock the broad market must deal with.
·13 t sitten · MuokattuHeart, CNS/central nervous system/brain, eye, muscles, lungs, kidneys, autoimmune diseases, cancer, cell therapies, vaccines - projects with circVec are now underway worldwide, USA, Europe, Asia, Canada. The activity is massive and much is being done and paid for by partners who see the potential in the technology to combine it with their own projects and their own technology. It is in the process of becoming an international technology. On August 31st, they have announced new results and Lubor van Gaal strongly recommended paying attention to the H1 presentation.
I'm just attaching my email again from the other day, with a reply from Erik Wiklund/Thomas Birkballe Hansen. In case some have missed it. It's going to go completely wild. 😎💰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
130 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sittenHi everyone, see the stock has risen A LOT in the last year. I actually know nothing about the company 😅. Should jrg buy? Or wait until it perhaps goes down?Listen carefully now, I'm only saying it once Investormark You skip Viking Lotto and Lotto and Europott Other games e.g. horse betting per week it costs kr300,- and you skip all the beers in town approx kr. 700.- taxi home from town kr 500,- per week kr 1500,- month kr 6000, Voila, not hungover now you have kr 6000,- per month now you are on your way 4 months kr 24000,- then you have approx 2,500 shares wait 3 years then this can be good multiply it by kr 150 or kr 550 🙂
- ·11 t sitten · MuokattuTime to give Investornytt and Teigland credit. This is well written. The share price has increased tenfold – now the real Circio journey begins https://www.investornytt.no/kommentar/tidoblet-kursen-na-begynner-den-virkelige-circio-reisen/541928 Circio has already been one of the year's biggest stock market rockets. After raising 628 million kroner, entering new international collaborations, and nominating an RNA heavyweight to the board, Espen Teigland believes the company has delivered a masterclass in biotechnological risk management and commercial positioning. FROM BIOTECH GNAT TO STOCK MARKET ROCKET: CEO Erik Digman Wiklund has lifted Circio from an overlooked biotech company to one of the year's biggest share price winners. After one tenfold increase, 628 million kroner raised, and several international collaborations in place, Wiklund believes the company can do it again. As a long-time observer and stock commentator, I have seen countless companies stumble into the same, well-known trap: One falls in love with one's own technology, burns through investors' capital on an expensive and solitary race towards the clinic, and ends up in an endless spiral of dilutive crisis emissions. Biotechnology on the Oslo Stock Exchange has therefore rightly gained a reputation as a binary roulette game. But what we are now witnessing from Circio after a formidable first half of 2026, appears to be something fundamentally different. The company is implementing a strategic shift that, in my opinion, makes them one of the most technologically and commercially exciting platform investments in Nordic biotech right now. The share has already increased tenfold in a short time. CEO Erik Digman Wiklund has previously stated to Investornytt that the company can do it again. After the milestones in the first half of the year, I do not believe the ambition appears less realistic – quite the opposite. The Achilles' heel in gene therapy To understand why these fresh milestones are so potent, we must delve into the scientific substance. Gene therapy has long struggled with a fundamental problem: delivery and expression. To get enough therapeutic protein produced in the body, patients often need to be given massive doses of viral vectors like AAV. This triggers immune responses, dangerous toxicity, and extreme production costs. Circio's proprietary circVec technology (based on circular RNA) addresses this by providing up to 75 times longer RNA half-life and up to 50 times higher protein expression than conventional mRNA vectors. Are you following? But it is the way the company is now commercializing and validating this that truly impresses me. Surgical intervention in the secretory bottleneck The partnership with Avenue Biosciences targets gene therapy's perhaps largest underutilized bottleneck – the cell's secretory pathways. Avenue uses machine learning to optimize signal peptides, i.e., the molecular codes that tell the cell to secrete the protein into the bloodstream rather than retaining it internally. When Circio now combines its long-lasting RNA expression with Avenue's ability to maximize secretion, they create a synergy that can dramatically reduce the required dose. If they prove that this combination works in vivo, circVec will go from being an interesting. Platform within more narrow gene therapy to becoming a plug-and-play solution for chronic diseases that require long-term expression of, for example, antibodies or peptides, such as e.g. rheumatism or obesity. An option on the future of immunotherapy Earlier this year, Circio announced several collaborations, including with Canadian Acuitas and German Tcelltech, where they aim for an even greater challenge: In vivo CAR-T cell therapy. Today, CAR-T is done ex vivo, where the patient's cells are harvested, manipulated in expensive laboratories over several weeks, and reinserted – a process that costs millions per patient. The entire industry is now chasing methods to inject the treatment directly into the body, but the use of viral vectors creates serious safety concerns. Acuitas develops LNP particles that can deliver genetic material specifically to the body's T-cells. There is currently enormous interest around in vivo (in the body) CAR-T and circRNA technology, which is clearly reflected in the market where companies like oRNA Tx, Orbital, and Sail Biomedicines have recently been acquired by Big Pharma for large sums for their programs. In this red-hot landscape, Tcelltech positions itself with a significant competitive advantage. The company possesses nanoSMAR, a non-viral, episomal DNA vector that stands out with its enormous cargo capacity. By combining this patented vector technology with the powerful gene expression from circVec, Tcelltech is now attempting to crack the very code for scalable cell therapy.Dr. Dinah Sah's professional seal of quality The perhaps most convincing indicator that Circio has moved into the elite league, we find neither in the test tubes nor in the partnerships, but in the nomination of Dr. Dinah Sah to the company's board. Sah is one of the pioneers behind modern RNA medicine. As former VP of Research at Alnylam Pharmaceuticals, she helped drive forward patisiran (ONPATTRO), the first approved RNAi therapy in history, before becoming CSO at Voyager Therapeutics, one of the pioneering companies in AAV gene therapy, which is Circio´s most advanced project. She knows exactly what it takes to get RNA and AAV technology through the regulatory needle's eye in the USA and all the way to clinical approval. Heavy, American research elite does not waste its time on castles in the air. Sah's entry is a professional endorsement in itself, and gives Circio an invaluable position when they are now to approach American venture capitalists and potential partners. 620 million in cash keeps the ghost of issuance away Ad All this professional foundation, however, rests on a solid financial ground. In the first half of 2026, the company carried out capital raises of approximately 620 million kroner. For a biotech investor, the absence of the famous "ghost of issuance" is alpha and omega. With this war chest, management has bought itself a solid runway well into 2030, with the goal of clinical initiation for the company's leading candidate in 2029. They are thus not forced to enter into suboptimal, rushed agreements with their back against the wall, but can negotiate with Big Pharma from a position of strength as preclinical data from the Avenue and Tcelltech collaborations mature. Shareholder verdict: A robust platform journey filled with value-driving triggers Although risk-free biotechnology does not exist, Circio shows how to systematically minimize company-specific risk. By diversifying the application areas, obtaining strong professional validation, and securing the cash, Circio transforms itself from a vulnerable single-product company to a unique and industry-leading technological platform concept. For shareholders, this means that the journey towards clinical initiation in 2029 will not be a long desert trek, but a period filled with continuous, value-driving triggers as technology synergies are confirmed in the market and the scope for partnership agreements grows. Circio steps out of the shadow and into the Main Index Also on the stock exchange, Circio is about to move up a division. DNB Carnegie expects the company to be included in both OSEBX and OSEFX at autumn's index rebalancing. If the prediction is confirmed, it can provide increased visibility, more institutional interest, and purchases from funds that follow the indices. This will in that case be yet another sign that Circio has gone from being an overlooked biotech gnat to a stock the broad market must deal with.
- ·13 t sitten · MuokattuHeart, CNS/central nervous system/brain, eye, muscles, lungs, kidneys, autoimmune diseases, cancer, cell therapies, vaccines - projects with circVec are now underway worldwide, USA, Europe, Asia, Canada. The activity is massive and much is being done and paid for by partners who see the potential in the technology to combine it with their own projects and their own technology. It is in the process of becoming an international technology. On August 31st, they have announced new results and Lubor van Gaal strongly recommended paying attention to the H1 presentation.I'm just attaching my email again from the other day, with a reply from Erik Wiklund/Thomas Birkballe Hansen. In case some have missed it. It's going to go completely wild. 😎💰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
130 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sittenHi everyone, see the stock has risen A LOT in the last year. I actually know nothing about the company 😅. Should jrg buy? Or wait until it perhaps goes down?Listen carefully now, I'm only saying it once Investormark You skip Viking Lotto and Lotto and Europott Other games e.g. horse betting per week it costs kr300,- and you skip all the beers in town approx kr. 700.- taxi home from town kr 500,- per week kr 1500,- month kr 6000, Voila, not hungover now you have kr 6000,- per month now you are on your way 4 months kr 24000,- then you have approx 2,500 shares wait 3 years then this can be good multiply it by kr 150 or kr 550 🙂
- ·11 t sitten · MuokattuTime to give Investornytt and Teigland credit. This is well written. The share price has increased tenfold – now the real Circio journey begins https://www.investornytt.no/kommentar/tidoblet-kursen-na-begynner-den-virkelige-circio-reisen/541928 Circio has already been one of the year's biggest stock market rockets. After raising 628 million kroner, entering new international collaborations, and nominating an RNA heavyweight to the board, Espen Teigland believes the company has delivered a masterclass in biotechnological risk management and commercial positioning. FROM BIOTECH GNAT TO STOCK MARKET ROCKET: CEO Erik Digman Wiklund has lifted Circio from an overlooked biotech company to one of the year's biggest share price winners. After one tenfold increase, 628 million kroner raised, and several international collaborations in place, Wiklund believes the company can do it again. As a long-time observer and stock commentator, I have seen countless companies stumble into the same, well-known trap: One falls in love with one's own technology, burns through investors' capital on an expensive and solitary race towards the clinic, and ends up in an endless spiral of dilutive crisis emissions. Biotechnology on the Oslo Stock Exchange has therefore rightly gained a reputation as a binary roulette game. But what we are now witnessing from Circio after a formidable first half of 2026, appears to be something fundamentally different. The company is implementing a strategic shift that, in my opinion, makes them one of the most technologically and commercially exciting platform investments in Nordic biotech right now. The share has already increased tenfold in a short time. CEO Erik Digman Wiklund has previously stated to Investornytt that the company can do it again. After the milestones in the first half of the year, I do not believe the ambition appears less realistic – quite the opposite. The Achilles' heel in gene therapy To understand why these fresh milestones are so potent, we must delve into the scientific substance. Gene therapy has long struggled with a fundamental problem: delivery and expression. To get enough therapeutic protein produced in the body, patients often need to be given massive doses of viral vectors like AAV. This triggers immune responses, dangerous toxicity, and extreme production costs. Circio's proprietary circVec technology (based on circular RNA) addresses this by providing up to 75 times longer RNA half-life and up to 50 times higher protein expression than conventional mRNA vectors. Are you following? But it is the way the company is now commercializing and validating this that truly impresses me. Surgical intervention in the secretory bottleneck The partnership with Avenue Biosciences targets gene therapy's perhaps largest underutilized bottleneck – the cell's secretory pathways. Avenue uses machine learning to optimize signal peptides, i.e., the molecular codes that tell the cell to secrete the protein into the bloodstream rather than retaining it internally. When Circio now combines its long-lasting RNA expression with Avenue's ability to maximize secretion, they create a synergy that can dramatically reduce the required dose. If they prove that this combination works in vivo, circVec will go from being an interesting. Platform within more narrow gene therapy to becoming a plug-and-play solution for chronic diseases that require long-term expression of, for example, antibodies or peptides, such as e.g. rheumatism or obesity. An option on the future of immunotherapy Earlier this year, Circio announced several collaborations, including with Canadian Acuitas and German Tcelltech, where they aim for an even greater challenge: In vivo CAR-T cell therapy. Today, CAR-T is done ex vivo, where the patient's cells are harvested, manipulated in expensive laboratories over several weeks, and reinserted – a process that costs millions per patient. The entire industry is now chasing methods to inject the treatment directly into the body, but the use of viral vectors creates serious safety concerns. Acuitas develops LNP particles that can deliver genetic material specifically to the body's T-cells. There is currently enormous interest around in vivo (in the body) CAR-T and circRNA technology, which is clearly reflected in the market where companies like oRNA Tx, Orbital, and Sail Biomedicines have recently been acquired by Big Pharma for large sums for their programs. In this red-hot landscape, Tcelltech positions itself with a significant competitive advantage. The company possesses nanoSMAR, a non-viral, episomal DNA vector that stands out with its enormous cargo capacity. By combining this patented vector technology with the powerful gene expression from circVec, Tcelltech is now attempting to crack the very code for scalable cell therapy.Dr. Dinah Sah's professional seal of quality The perhaps most convincing indicator that Circio has moved into the elite league, we find neither in the test tubes nor in the partnerships, but in the nomination of Dr. Dinah Sah to the company's board. Sah is one of the pioneers behind modern RNA medicine. As former VP of Research at Alnylam Pharmaceuticals, she helped drive forward patisiran (ONPATTRO), the first approved RNAi therapy in history, before becoming CSO at Voyager Therapeutics, one of the pioneering companies in AAV gene therapy, which is Circio´s most advanced project. She knows exactly what it takes to get RNA and AAV technology through the regulatory needle's eye in the USA and all the way to clinical approval. Heavy, American research elite does not waste its time on castles in the air. Sah's entry is a professional endorsement in itself, and gives Circio an invaluable position when they are now to approach American venture capitalists and potential partners. 620 million in cash keeps the ghost of issuance away Ad All this professional foundation, however, rests on a solid financial ground. In the first half of 2026, the company carried out capital raises of approximately 620 million kroner. For a biotech investor, the absence of the famous "ghost of issuance" is alpha and omega. With this war chest, management has bought itself a solid runway well into 2030, with the goal of clinical initiation for the company's leading candidate in 2029. They are thus not forced to enter into suboptimal, rushed agreements with their back against the wall, but can negotiate with Big Pharma from a position of strength as preclinical data from the Avenue and Tcelltech collaborations mature. Shareholder verdict: A robust platform journey filled with value-driving triggers Although risk-free biotechnology does not exist, Circio shows how to systematically minimize company-specific risk. By diversifying the application areas, obtaining strong professional validation, and securing the cash, Circio transforms itself from a vulnerable single-product company to a unique and industry-leading technological platform concept. For shareholders, this means that the journey towards clinical initiation in 2029 will not be a long desert trek, but a period filled with continuous, value-driving triggers as technology synergies are confirmed in the market and the scope for partnership agreements grows. Circio steps out of the shadow and into the Main Index Also on the stock exchange, Circio is about to move up a division. DNB Carnegie expects the company to be included in both OSEBX and OSEFX at autumn's index rebalancing. If the prediction is confirmed, it can provide increased visibility, more institutional interest, and purchases from funds that follow the indices. This will in that case be yet another sign that Circio has gone from being an overlooked biotech gnat to a stock the broad market must deal with.
- ·13 t sitten · MuokattuHeart, CNS/central nervous system/brain, eye, muscles, lungs, kidneys, autoimmune diseases, cancer, cell therapies, vaccines - projects with circVec are now underway worldwide, USA, Europe, Asia, Canada. The activity is massive and much is being done and paid for by partners who see the potential in the technology to combine it with their own projects and their own technology. It is in the process of becoming an international technology. On August 31st, they have announced new results and Lubor van Gaal strongly recommended paying attention to the H1 presentation.I'm just attaching my email again from the other day, with a reply from Erik Wiklund/Thomas Birkballe Hansen. In case some have missed it. It's going to go completely wild. 😎💰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt